ethyl 4-{[4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino}benzoate | 893420-51-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 4-{[4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino}benzoate
• 英文别名: ethyl 4-[[4-(2-methyl-3-propan-2-ylimidazol-4-yl)pyrimidin-2-yl]amino]benzoate
• CAS: 893420-51-4
• 化学式: C₂₀H₂₃N₅O₂
• 分子量: 365.435
• InChiKey: SLDZNFYYDSZKEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  81.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 4-{[4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino}benzoate 在 sodium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 生成 4-{[4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino}benzoic acid
  参考文献：
  名称：

  The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing

  摘要：

  The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described. Optimisation of inhibitory potency against multiple CDK's (1, 2 and 9) resulted in imidazole pyrimidine amides with potent in vitro anti-proliferative effects against a range of cancer cell lines. Excellent physiochemical properties and large margins against inhibition of CYP isoforms and the hERG ion channel were achieved by modi. cation of lipophilicity and amine basicity. A candidate with disease model activity in human cancer cell line xenografts and with suitable physiochemical and pharmacokinetic profiles for intravenous (iv) dosing was selected for further development as AZD5597. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.102
• 作为产物：
  描述：

  4-(2-甲基-3-(丙烷-2-基)-3H-咪唑-4-基)嘧啶-2-胺 、 对碘苯甲酸乙酯 在 palladium diacetate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 caesium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 以31%的产率得到ethyl 4-{[4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino}benzoate
  参考文献：
  名称：

  WO2007/148070

  摘要：

  公开号：

文献信息

• 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
  申请人：Andrews David

  公开号：US20090099160A1

  公开（公告）日：2009-04-16

  Compounds of the formula (I): wherein variable groups are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  化合物的公式（I）：其中变量基团如定义中所述，并描述了药物可接受的盐和体内可水解酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为产生细胞周期抑制（抗细胞增殖）作用的药物，用于温血动物，如人。
• Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders
  申请人：Andrews David

  公开号：US20080280906A1

  公开（公告）日：2008-11-13

  Compounds of formula (I): which possess cell-cycle inhibitory activity are described.

  描述了具有细胞周期抑制活性的化合物，其化学式为（I）。
• CHEMICAL COMPOUNDS
  申请人：Jones Clifford

  公开号：US20100240686A1

  公开（公告）日：2010-09-23

  Compounds of formula (I): which possess cell-cycle inhibitory activity are described.

  描述了具有细胞周期抑制活性的化合物，其化学式为(I)。
• Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
  申请人：AstraZeneca AB

  公开号：EP2301928A1

  公开（公告）日：2011-03-30

  Compounds of formula (I): which possess cell-cycle inhibitory activity are described.

  式(I)化合物： 所述化合物具有细胞周期抑制活性。
• WO2007/15064
  申请人：——

  公开号：——

  公开（公告）日：——